Sirio Pharma Co Ltd
SZSE:300791
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.5449
27.44
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Sirio Pharma Co Ltd
Operating Income
Sirio Pharma Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Sirio Pharma Co Ltd
SZSE:300791
|
Operating Income
ÂĄ453.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Hengan International Group Company Ltd
HKEX:1044
|
Operating Income
ÂĄ3.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Proya Cosmetics Co Ltd
SSE:603605
|
Operating Income
ÂĄ1.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
By-health Co Ltd
SZSE:300146
|
Operating Income
ÂĄ826.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
5%
|
|
|
S
|
Shanghai Chicmax Cosmetic Co Ltd
HKEX:2145
|
Operating Income
ÂĄ933.9m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
Operating Income
ÂĄ2.3B
|
CAGR 3-Years
36%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Sirio Pharma Co Ltd
Glance View
Sirio Pharma Co. Ltd. manufactures dietary supplement products. The company is headquartered in Shantou, Guangdong and currently employs 2,456 full-time employees. The company went IPO on 2019-09-25. The firm's main products include soft capsules, tablets, powders, soft candy, hard capsules and oral liquids. The firm's own brand is WEWOW nutritional health food. The firm distributes its products both in the domestic market and to overseas markets.
See Also
What is Sirio Pharma Co Ltd's Operating Income?
Operating Income
453.1m
CNY
Based on the financial report for Sep 30, 2025, Sirio Pharma Co Ltd's Operating Income amounts to 453.1m CNY.
What is Sirio Pharma Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
14%
Over the last year, the Operating Income growth was -2%. The average annual Operating Income growth rates for Sirio Pharma Co Ltd have been 24% over the past three years , 14% over the past five years .